Related Experiment Video
Updated: Jun 21, 2026
Using Microarrays to Interrogate Microenvironmental Impact on Cellular Phenotypes in Cancer
Published on: May 21, 2019
Microarray analysis of MCF-7 breast cancer cells treated with 1,25-dihydroxyvitamin D3 or a 17-methyl-D-ring analog
Els Vanoirbeek1, Guy Eelen, Lieve Verlinden
1Laboratorium voor Experimentele Geneeskunde en Endocrinologie, Katholieke Universiteit Leuven, Gasthuisberg, 3000 Leuven, Belgium.
Background:
1alpha,25-Dihydroxyvitamin D3 [1,25-(OH)2D3] is the biological active form of vitamin D. Its antiproliferative capacities make it a potential drug to treat diseases such as cancer. The clinical use of 1,25-(OH)2D3 as an antiproliferative agent is hampered by its calcemic effects. Hence, structural analogs such as the seco-9,11-bisnor-17-methyl analog, WY1112, have been developed with superagonistic capacities. This study aims to distinct the molecular activities of 1,25-(OH)2D3 and WY1112 and identify possible differences in gene expression.
Materials And Methods:
Total RNA was extracted from MCF-7 breast cancer cells treated with 1,25-(OH)2D3 or WY1112 and was used for microarray analysis.
Results:
The experiments revealed that WY1112 induces the same genes as 1,25-(OH)2D3, but the induction level of the individual genes is higher. Microarray analysis did not reveal genes that were exclusively regulated by WY1112.
Conclusion:
The superagonistic vitamin D analog WY1112 induces the same set of genes as 1,25-(OH)2D3, but the level of induction of the individual genes is higher.
More Related Videos
11:06Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells
Published on: May 20, 2015
10:55Analyzing the Communication Between Monocytes and Primary Breast Cancer Cells in an Extracellular Matrix Extract (ECME)-based Three-dimensional System
Published on: January 8, 2018